
OBJECTIVE: Online screening may facilitate help-seeking behavior among individuals at risk for psychosis, although adolescents rarely advance beyond information gathering. This study aimed to investigate adolescents' help-seeking actions, interests, and barriers to inform early intervention strategies. METHODS: A digital pathway was developed to screen, assess, and refer at-risk participants to care. This report presents preliminary trial data of adolescents (ages 12-17) seeking help online. RESULTS: In the trial's first 9 months, 7,944 adolescents had a positive online screen for psychosis risk; 91 (1.1%) advanced to texting with a peer navigator, and four (0.1%) advanced to assessment. Two of the four adolescents referred to care successfully initiated treatment; 25 offered explanations for not seeking care, most often because of reluctance to involve a caregiver (52%). CONCLUSIONS: Adolescents are particularly susceptible to screening positive for psychosis risk, yet few subsequently seek help. Disclosure to caregivers may be a critical step to obtaining care for this population.
Recent developments at the NIH raise concerns that the agency is narrowing its definition of mission-relevant research to exclude studies evaluating the effects of public policies or explicitly seeking to generate evidence for policymakers. This position piece outlines five reasons why policy research and engagement with policymakers should remain within the scope of NIH-supported mental health and substance use (i.e., behavioral health) research. First, public policies shape behavioral health outcomes at a population scale, and exclusion of policy research would therefore undermine efforts to understand and improve behavioral health outcomes. Second, policy research is integral to translational behavioral health science-including science that is focused on clinical interventions. Third, effective evidence-informed policymaking-such as that envisioned by the Foundations for Evidence-Based Policymaking Act of 2018-requires policy-relevant research evidence. Fourth, communicating findings from policy research is not lobbying or advocacy per NIH definitions. Fifth, policy research represents a small share of NIH funding, accounting for approximately 2% of NIMH funding. NIH's mission is to generate knowledge that improves health. Understanding how policy shapes health-and communicating that knowledge to those responsible for policymaking-is essential to fulfilling that mission.
OBJECTIVE: Veterans with general medical or mental health conditions that were caused or exacerbated by military service may be eligible for U.S. Department of Veterans Affairs (VA) service-connected disability compensation, which entails financial support, access to health care, and long-term benefits. Using a contemporary, nationally representative sample of U.S. military veterans, the authors compared the sociodemographic, military, and clinical characteristics of veterans with and of those without service-connected disability and identified factors associated with receipt of benefits for mental health versus general medical conditions. METHODS: Data were analyzed from 2,636 U.S. military veterans who participated in the National Health and Resilience in Veterans Study. Participants reported service-connected disability status, disability rating, and primary service-connected conditions and completed assessments for sociodemographic characteristics, military status, trauma exposure, psychiatric disorders, and general medical conditions. RESULTS: Overall, 39% of veterans reported having a VA service-connected disability. Multivariable analyses indicated that younger age, longer military service, a greater number of deployments, lifetime psychiatric diagnosis, and greater medical burden were independently associated with increased odds of receiving service-connected disability benefits. Having a service-connected psychiatric disability was strongly associated with lifetime psychiatric diagnosis, a greater number of deployments, and military sexual trauma. CONCLUSIONS: A substantial percentage of U.S. veterans receive service-connected disability benefits. Veterans receiving these benefits represent a clinically complex population with substantial cumulative service-related exposures and elevated mental and general medical health burdens. These findings may inform clinical care, resource allocation, and policies aimed at addressing the long-term health needs of veterans with service-connected disabilities.
Experimental therapeutics is a framework focused on measuring whether experimentally manipulated, hypothesized targets of an intervention produce changes in clinical outcomes. For example, if a novel receptor is identified in schizophrenia and researchers believe that targeting that receptor would reduce paranoid delusions, researchers would then develop a drug targeting that receptor and test whether that drug reduces paranoid delusions. Although experimental therapeutics has generated a lot of excitement about highly individualized psychiatric treatments, there are questions as to its promise. Namely, such treatments have not produced the anticipated results despite ample funding support. Although psychiatry needs new models and innovations, the efficacy of experimental therapeutics as the path to identify these models and innovations remains questionable. therapeutics framework to the proposed work incurs additional prerequisites, namely, knowing why an intervention works to be considered for funding. The two perspectives selected for this column are both skeptical that having an experimental therapeutics perspective is productive, but they take different positions. Dr. Freed and coauthors advocate that experimental therapeutics frameworks take a more inclusive approach, highlighting the disadvantages of a narrow-door strategy. Dr. Rolin and colleagues argue that the experimental therapeutics framework should be replaced by a different framework that is based on desirability of outcomes. We hope that this exchange provides a useful perspective on a controversy that may not be on everyone's radar but has an impact on the pipeline of future therapeutics used to treat the patients psychiatrists serve.